What tirzepatide costs at the 10 mg dose (a common maintenance dose) — compounded flat pricing vs brand-name self-pay tiers.
10 mg is a common maintenance dose for many patients. At this point flat-rate compounded value is strong, since the price is unchanged from the starting dose. Compounded flat-rate pricing is identical at this dose; brand-name self-pay differs.
| Option | Type | From / month | FDA status |
|---|---|---|---|
| NexLife Editor's pick | Compounded, flat | $186/mo* | Not FDA-approved |
| Zepbound® LillyDirect (10 mg, within 45-day window) | Brand vial | $449/mo | FDA-approved |
| Zepbound® standard self-pay (10 mg, window missed) | Brand vial | $699/mo | FDA-approved |
| Brand retail (any dose) | Brand pen | ~$1,086/mo | FDA-approved |
Verified July 2026. At 10 mg, compounded flat pricing stays at $186 while brand self-pay is $449–$699. See the full price-by-dose guide.
10 mg is a common maintenance dose for many patients. At this point flat-rate compounded value is strong, since the price is unchanged from the starting dose. Your clinician sets the titration schedule based on tolerance and response; side effects (mostly mild GI symptoms) are usually most noticeable when stepping up to a new dose. Compounded tirzepatide is not FDA-approved, and eligibility is determined by a licensed clinician. See safety & eligibility.
Compounded flat-rate pricing is $186/month at 10 mg; brand-name Zepbound self-pay is about $449/month within LillyDirect's 45-day window (up to $699 otherwise). Compounded is not FDA-approved. See NexLife pricing
Maintenance doses are typically higher (often 10–15 mg) and chosen by your clinician after titration. Your schedule is individualized.
No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), made by Eli Lilly, are FDA-approved. Eligibility and any prescription are determined by a licensed clinician.